Understanding factors that lead to hypothyroidism after radioactive iodine treatment for Graves' disease
Factors Affecting Timing of Hypothyroidism Following Radioactive Iodine Therapy Patients With Graves Disease
This study looks at what factors might cause some people with Graves' disease to develop low thyroid hormone levels after receiving radioactive iodine treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 13 Years to 70 Years |
| Sex | All |
| Sponsor | Assiut University Academic / other |
| Locations | 1 site (Assiut) |
| Trial ID | NCT05643365 on ClinicalTrials.gov |
What this trial studies
This observational study aims to identify risk factors associated with the onset of early hypothyroidism following radioactive iodine (RAI) therapy in patients diagnosed with Graves' disease. It focuses on analyzing data from patients who have undergone RAI treatment and examines various clinical parameters such as thyroid weight, thyroid-stimulating hormone levels, and thyroid volume. By clarifying these risk factors, the study seeks to enhance understanding of the side effects of RAI therapy and improve patient management post-treatment.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with Graves' disease who have undergone radioactive iodine therapy at least one year prior.
Not a fit: Patients with other causes of hyperthyroidism, thyroid cancer, or those who have had previous thyroid surgery may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could help identify patients at higher risk for hypothyroidism, allowing for better monitoring and management strategies.
How similar studies have performed: While the study addresses a known issue in the management of Graves' disease, similar studies have shown varying results regarding the risk factors for hypothyroidism post-RAI therapy, indicating that this area still requires further investigation.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Graves' disease patients after one year of RAI therapy . 2. Suppressed serum thyrotropin (TSH) \<0.55 µU/ml , elevated serum free triiodothyronine (FT3) \> 6.5 pmol/L , free thyroxin FT4 \>22.7 pmol/L . Exclusion Criteria: 1. Patients with other causes of hyperthyroidism , such as toxic multinodular goiter and single toxic adenoma 2. Thyroid cancer 3. Recurrent GD 4. Previous Thyroid surgery 5. Patients can't complete the follow -up within 6 months.
Where this trial is running
Assiut
- Nuclear medicine unit, department of clinical oncology and nuclear medicine, Assiut university hospital — Assiut, Egypt (Recruiting)
Study contacts
- Study coordinator: Aya A Alsanory, Master
- Email: ayota17@gmail.com
- Phone: 00201063490867
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.